Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

3.

Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.

Blasi E, Bamberger M, Knight D, Engwall M, Wolk R, Winter S, Betts A, John-Baptiste A, Keiser J.

J Cardiovasc Pharmacol. 2009 Jun;53(6):507-16. doi: 10.1097/FJC.0b013e3181a8184c.

PMID:
19455053
4.

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.

de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC.

Circulation. 2008 May 13;117(19):2515-22. doi: 10.1161/CIRCULATIONAHA.107.761965. Epub 2008 May 5.

5.
6.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
7.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators.

N Engl J Med. 2007 Apr 19;356(16):1620-30. Epub 2007 Mar 26.

8.
11.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

12.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators.

Lancet. 2007 Jul 14;370(9582):153-60.

PMID:
17630038
13.

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter P.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):10E-5E. doi: 10.1016/j.amjcard.2009.09.014.

PMID:
19895939
14.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ.

Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18.

15.

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Shinkai H.

Expert Opin Ther Pat. 2009 Sep;19(9):1229-37. doi: 10.1517/13543770903198451. Review.

PMID:
19663630
16.

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Cohn JS, Wilson A, Wolfe ML, Nartsupha C, Schaefer PM, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

J Lipid Res. 2008 Mar;49(3):543-9. Epub 2007 Nov 21.

17.

Effect of torcetrapib on the progression of coronary atherosclerosis.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators.

N Engl J Med. 2007 Mar 29;356(13):1304-16. Epub 2007 Mar 26. Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P].

18.

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1350-6. Epub 2006 Mar 30.

19.

Renin-angiotensin-aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects.

Krikken JA, Dallinga-Thie GM, Navis G, Dullaart RP.

Expert Opin Ther Targets. 2008 Nov;12(11):1321-8. doi: 10.1517/14728222.12.11.1321 .

PMID:
18851690
20.

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.

Vergeer M, Stroes ES.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):32E-8E. doi: 10.1016/j.amjcard.2009.09.017. Review.

PMID:
19895942

Supplemental Content

Support Center